Agamree (Vamorolone) for Muscular dystrophy

Overview
Agamree is approved by the U.S. Food and Drug Administration (FDA) for treating Duchenne muscular dystrophy (DMD) in people ages 2 years and older. It is prescribed for managing symptoms associated with DMD, a progressive muscle-wasting disorder. Agamree is also known by its drug name, vamorolone.

Vamorolone is a corticosteroid, a class of medications that can reduce inflammation and suppress the immune response. In treating DMD, it is thought to help delay muscle deterioration by targeting inflammation that contributes to muscle damage.

How do I take it?
Prescribing information states that Agamree is taken as an oral suspension, typically once daily with a meal. For most people, the recommended dosage is based on body weight and is adjusted in cases of mild to moderate liver impairment. Gradual dose reduction is advised for those taking Agamree for more than one week. This medication should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Agamree include cushingoid features (round or puffy face), psychiatric disorders, vomiting, weight gain, and vitamin D deficiency.

Rare but serious side effects may include adrenal suppression (reduced hormone production by the adrenal glands), increased risk of infection, high blood pressure, electrolyte imbalances, kidney (renal) and cardiovascular issues, gastrointestinal perforation (hole in the stomach or intestine), mood changes, bone density loss, and eye conditions like cataracts and glaucoma. Individuals receiving immunosuppressive doses of Agamree should avoid live vaccines, which may increase the risk of infection.

For more information about this treatment, visit:

Label: Agamree — Vamorolone Kit — DailyMed